Результати пошуку - Sandrine Hiret

  • Показ 1 - 13 результатів із 13
Уточнити результати
  1. 1
    Phase I study of bromohydrin pyrophosphate (BrHPP, IPH 1101), a Vγ9Vδ2 T lymphocyte agonist in patients with solid tumors

    Phase I study of bromohydrin pyrophosphate (BrHPP, IPH 1101), a Vγ9Vδ2 T lymphocyte agonist in patients with solid tumors за авторством Jaafar Bennouna, Vincent Lévy, Hélène Sicard, Hélène Senellart, Marie Audrain, Sandrine Hiret, Frédéric Rolland, Heriberto Bruzzoni‐Giovanelli, Marie Rimbert, Céline Galéa, Jérôme Tiollier, Fabien Calvo

    Опубліковано 2010
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  2. 2
    Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%

    Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50% за авторством Elvire Pons‐Tostivint, P. Hulo, V. Guardiolle, L. Bodot, Audrey Rabeau, M. Porte, Sandrine Hiret, Pierre Demontrond, H. Curcio, A. Boudoussier, Rémi Veillon, M. Mayenga, Coraline Duménil, Thierry Chatellier, Pierre‐Antoine Gourraud, Julien Mazières, Jaafar Bennouna

    Опубліковано 2023
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  3. 3
    Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in <i>KRAS</i> Wild-Type Metastatic Colorectal Cancer

    Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in <i>KRAS</i> Wild-Type Metastatic Colorectal Cancer за авторством Jaafar Bennouna, Sandrine Hiret, Aurélie Bertaut, Olivier Bouché, G. Deplanque, Christian Borel, Éric François, Thierry Conroy, François Ghiringhelli, G. Des Guetz, Jean‐François Seitz, Pascal Artru, Mohamed Hebbar, Trevor Stanbury, Marc G. Denis, Antoine Adenis, Christophe Borg

    Опубліковано 2018
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  4. 4
    First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743

    First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743 за авторством Solange Peters, Arnaud Scherpereel, Robin Cornelissen, Youssef Oulkhouir, Laurent Greillier, Kaplan Ma, Thomas Talbot, I. Monnet, Sandrine Hiret, Paul Baas, Anna K. Nowak, Nobukazu Fujimoto, Anne S. Tsao, Aaron S. Mansfield, Sanjay Popat, X. Zhang, Nan Hu, David Balli, Thomas E. Spires, Gérard Zalcman

    Опубліковано 2022
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  5. 5
    Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non–small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study

    Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non–small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study... за авторством Alexis B. Cortot, Clarisse Audigier-Valette, Olivier Molinier, Sylvestre Le Moulec, Fabrice Barlési, Gérard Zalcman, Patrick Dumont, Damien Pouessel, Claire Poulet, C. Fontaine-Delaruelle, Sandrine Hiret, A. Dixmier, P Renault, Catherine Becht, Olivier Raffy, C. Dayen, Julien Mazières, Éric Pichon, Alexandra Langlais, Franck Morin, Denis Moro‐Sibilot, Benjamin Besse

    Опубліковано 2020
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  6. 6
    Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial

    Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 t... за авторством Arnaud Scherpereel, Julien Mazières, Laurent Greillier, Sylvie Lantuéjoul, Pascal Dô, Olivier Bylicki, I. Monnet, R. Corre, Clarisse Audigier-Valette, M. Locatelli-Sanchez, Olivier Molinier, Florian Guisier, T. Urban, Catherine Ligeza‐Poisson, David Planchard, Elodie Amour, Franck Morin, Denis Moro‐Sibilot, Gérard Zalcman, D. Debieuvre, Sandrine Hiret, Jacques Cadranel, S. Fraboulet-Moreau, D. Carmier

    Опубліковано 2019
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  7. 7
    High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome

    High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome за авторством Laura Mezquita, Maria Jové, Ernest Nadal, Maria Kfoury, Teresa Morán, Charles Ricordel, Marion Dhooge, Camille Tlemsani, H. Léna, Àlex Teulé, Jose-Valero Álvarez, Judith Raimbourg, Sandrine Hiret, Ludovic Lacroix, Mireia Menéndez, Juana Saldaña, Joan Brunet, P. Lianes, Isabelle Coupier, Édouard Auclin, Gonzalo Recondo, Luc Friboulet, Julien Adam, Emma Green, David Planchard, Thierry Frébourg, Gabriel Capellà, Étienne Rouleau, Conxi Lázaro, Olivier Caron, Benjamin Besse

    Опубліковано 2020
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  8. 8
    Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

    Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer за авторством Scott Antonia, Augusto Villegas, Davey B. Daniel, David Vicente, Shuji Murakami, Rina Hui, Takashi Yokoi, Alberto Chiappori, Ki Hyeong Lee, Maike de Wit, Byoung Chul Cho, Maryam Bourhaba, Xavier Quantin, Takaaki Tokito, Tarek Mekhail, David Planchard, Young‐Chul Kim, Christos S. Karapetis, Sandrine Hiret, Gyula Ostoros, Kaoru Kubota, Jhanelle E. Gray, Luis Paz‐Ares, Javier de Castro, Catherine Wadsworth, Giovanni Melillo, Haiyi Jiang, Yifan Huang, Phillip A. Dennis, Mustafa Özgüroğlu

    Опубліковано 2017
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  9. 9
    Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

    Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC за авторством Scott Antonia, Augusto Villegas, Davey B. Daniel, David Vicente, Shuji Murakami, Rina Hui, Takayasu Kurata, Alberto Chiappori, Ki Hyeong Lee, Maike de Wit, Byoung Chul Cho, Maryam Bourhaba, Xavier Quantin, Takaaki Tokito, Tarek Mekhail, David Planchard, Young‐Chul Kim, Christos S. Karapetis, Sandrine Hiret, Gyula Ostoros, Kaoru Kubota, Jhanelle E. Gray, Luis Paz‐Ares, Javier de Castro, Corinne Faivre‐Finn, Martin Reck, Johan Vansteenkiste, David R. Spigel, Catherine Wadsworth, Giovanni Melillo, Maria Taboada, Phillip A. Dennis, Mustafa Özgüroğlu

    Опубліковано 2018
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  10. 10
    Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies

    Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-B... за авторством Alessandro Parisi, Blandine Delaunay, Giada Pinterpe, Antoine Hollebecque, Jean Frédéric Blanc, Mohamed Bouattour, Eric Assenat, Méher Ben Abdelghani, Matthieu Sarabi, Monica Niger, Caterina Vivaldi, Mario Mandalà, Andrea Palloni, Maria Bensi, Silvio Ken Garattini, David Tougeron, Pierre Combe, Massimiliano Salati, Margherita Rimini, Chiara Alessandra Cella, Marco Tucci, Anna Diana, Elena Mori, Raffaella Longarini, Pascal Artru, Gaël Roth, Ludovic Evesque, A Vienne, Anthony Turpin, Sandrine Hiret, Vincent Bourgeois, Camille Hervé, Rodolphe Paulon, Marion Stacoffe, David Malka, Cindy Neuzillet, Julien Edeline, Astrid Lièvre, Rosine Guimbaud, Marie Christelle Pajiep Chapda, Lorenza Rimassa, Riccardo Giampieri, Juan W. Valle, Rossana Berardi, Nadim Farés

    Опубліковано 2024
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  11. 11
    PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon

    PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon за авторством Benoı̂t Rousseau, Ivan Bièche, Éric Pasmant, Nadim Hamzaoui, Nicolas Leulliot, Lucas Michon, Aurélien de Reyniès, Valerie Attignon, Michael B. Foote, Julien Masliah‐Planchon, Magali Svrcek, Romain Cohen, Victor Simmet, Paule Augereau, David Malka, Antoine Hollebecque, Damien Pouessel, Carlos Gomez‐Roca, Rosine Guimbaud, Amandine Bruyas, Marielle Guillet, Jean‐Jacques Grob, Muriel Duluc, Sophie Cousin, Christelle de la Fouchardière, Aude Fléchon, Frédéric Rolland, Sandrine Hiret, Esma Saâda-Bouzid, Olivier Bouché, Thierry André, Diane Pannier, Farid El Hajbi, Stéphane Oudard, Christophe Tournigand, Jean‐Charles Soria, Stéphane Champiat, Drew Gerber, Dennis Stephens, Michelle F. Lamendola-Essel, Steven B. Maron, Bill H. Diplas, Guillem Argilés, Asha Krishnan, Séverine Tabone–Eglinger, Anthony Ferrari, Neil H. Segal, Andrea Cercek, Natalie Hoog-Labouret, Frédéric Legrand, Clotilde Simon, Assia Lamrani-Ghaouti, Luis A. Díaz, Pierre Saintigny, Sylvie Chevret, Aurélien Marabelle

    Опубліковано 2022
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  12. 12
    Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study

    Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study за авторством Luis Paz‐Ares, Óscar Juan, Giannis Mountzios, Enriqueta Felip, Niels Reinmuth, Filippo de Marinis, Nicolas Girard, Vipul M. Patel, Takayuki Takahama, Scott Owen, Douglas Reznick, Firas Badin, İrfan Çiçin, Sabeen Mekan, Riddhi Patel, Éric Zhang, Divyadeep Karumanchi, Marina Chiara Garassino, Elizabeth Ahern, Venessa Chin, Stephen Della‐Fiorentina, Kevin Jasas, Christos S. Karapetis, Jeremy Long, Louise Nott, Kenneth J. O’Byrne, Craig Underhill, Richard Greil, Maximilian J. Hochmair, Andreas Pircher, Wim Demey, Paul Germonpré, Elke Govaerts, Thierry Pieters, Reinier Wener, Alan A. Azambuja, Giuliano Santos Borges, Gilberto de Castro, Suellen Castro, Felipe Melo Cruz, Fábio Franke, Eduardo Silva, Parneet Cheema, Robert H. El-Maraghi, Swati Kulkarni, Rami Nassabein, Scott Owen, Clarisse Audigier-Valette, Jaafar Bennouna, C. Chouaïd, Alexis B. Cortot, S. Couraud, D. Debieuvre, Fabrice Denis, Patrick Dumont, Radj Gervais, Nicolas Girard, Etienne Giroux‐Leprieur, Florian Guisier, Sandrine Hiret, Henri Janicot, Corinne Lamour, J. Madelaine, M. Marcq, E. Pluquet, Jean Louis Pujol, Magali Ravoire, Marielle Sabatini, A. Vergnenègre, Sabine Bohnet, Martin Faehling, Melanie Janning, Eckart Laack, Niels Reinmuth, Achim Rittmeyer, Claas Wesseler, Sofia Baka, George Fountzilas, Panagiotis Katsaounis, Athanasios Κotsakis, Ioannis Mountzios, Konstantinos Syrigos, Julia Dudnik, Fink Carmel, Ofer Merimsky, Hovav Nechushtan, Julia Sobolev, Franceso Agustoni, Anna Bettini, Matteo Brighenti, Giulio Cerea, Filippo de Marinis, Salvatore Grisanti, Francesco Grossi, Andrea Luciani, Evaristo Maiello, Héctor Soto Parrà, Pierfrancesco Tassone, Giuseppe Tonini, Yoko Agemi

    Опубліковано 2024
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  13. 13
    Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

    Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study за авторством Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim, Julien Mazières, Johan Vansteenkiste, H. Léna, Jesus Corral Jaime, Jhanelle E. Gray, John D. Powderly, C. Chouaïd, Paolo Bidoli, Paul Wheatley‐Price, Keunchil Park, Ross A. Soo, Yifan Huang, Catherine Wadsworth, Phillip A. Dennis, Naiyer A. Rizvi, Luis Paz-Ares Rodríguez, Silvia Novello, Sandrine Hiret, Peter Schmid, Eckart Laack, Raffaele Califano, Makoto Maemondo, Sang‐We Kim, Jamie E. Chaft, David Vicente Baz, Thierry Berghmans, Dong‐Wan Kim, Veerle Surmont, Martin Reck, Ji‐Youn Han, Esther Holgado Martin, Cristóbal Belda-Iniesta, Yuichiro Oe, Antonio Chella, Akhil Chopra, G. Robinet, Héctor Soto Parrà, Michael J. Thomas, Parneet Cheema, Nobuyuki Katakami, Wu‐Chou Su, Young‐Chul Kim, Juergen Wolf, Jong-Seok Lee, Hideo Saka, Michele Stanislaw Milella, Inmaculada Ramos García, Anne Sibille, Takashi Yokoi, Eun Joo Kang, Shinji Atagi, E. Spaeth-Schwalbe, Makoto Nishio, Fumio Imamura, Nashat Gabrail, Rémi Veillon, Sofie Derijcke, Tadashi Maeda, Dylan M. Zylla, Kendra Kubiak, Armando Santoro, Ma. Noemi Uy, Sarayut Lucien Geater, Antoîne Italiano, Dariusz M. Kowalski, Fabrice Barlési, Yuh‐Min Chen, David R. Spigel, Busyamas Chewaskulyong, Ramón García Gómez, Rosa Álvarez, James Chih‐Hsin Yang, Te‐Chun Hsia, Fabrice Denis, Hiroshi Sakai, Mark Vincent, Kōichi Goto, Joaquím Bosch-Barrera, Glen J. Weiss, Jean-Luc Canon, Christian W. Scholz, Massimo Aglietta, Hirotsugu Kemmotsu, Koichi Azuma, Penelope A. Bradbury, Ronald Feld, Abraham Chachoua, Jacek Jassem, Rosalyn A. Juergens, Ramón Palmero, Albert Malcolm, Nandagopal Vrindavanam, Kaoru Kubota, Cornelius F. Waller, David Waterhouse, Bruno Coudert, Z. Mark

    Опубліковано 2018
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:

Інструменти для пошуку: